Ubs Asset Management Americas Inc Immunovant, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 279,252 shares of IMVT stock, worth $7.68 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
279,252
Previous 310,830
10.16%
Holding current value
$7.68 Million
Previous $8.55 Million
10.15%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IMVT
# of Institutions
218Shares Held
67.1MCall Options Held
2.48MPut Options Held
561K-
Vanguard Group Inc Valley Forge, PA6.68MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$165 Million7.27% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$141 Million0.08% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.87MShares$106 Million1.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...